Ono Pharmaceutical Co. v. Dana-Farber Cancer Institute, Inc.

 
DOCKET NO.
OP. BELOW
SUBJECT
Patent

Question(s) Presented

“Whether the Federal Circuit erred in adopting a bright-line rule that the novelty and non-obviousness of an invention over alleged contributions that were already in the prior art are ‘not probative’ of whether those alleged contributions were significant to conception.”

Posts About this Case

Date
Proceedings and Orders
April 7, 2021
Motion to extend the time to file a response is granted and the time is extended to and including April 20, 2021.
May 4, 2021
DISTRIBUTED for Conference of 5/20/2021.
May 24, 2021
Petition DENIED. Justice Breyer took no part in the consideration or decision of this petition.